• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?

    Simply Wall St·07/28/2026 18:22:08
    语音播报

    HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and development of biologic drugs.

    See our latest analysis for HBM Holdings.

    Against this backdrop, HBM Holdings has been volatile, with the share price falling 1.74% over the past day but posting a 23.26% 1 month share price return. The 3 year total shareholder return is very large, signalling strong longer term momentum despite some recent setbacks.

    If this kind of biotech news has your attention, it could be a good moment to see what else is moving in healthcare by checking out 127 healthcare AI stocks

    After HBM Holdings' sharp 1 month rebound and the wide gap between the current HK$12.40 price and analyst and intrinsic value estimates, the next step is to identify where fair value most plausibly sits.

    Price-to-Earnings of 15x: Is it justified?

    On pure earnings terms, HBM Holdings trades on a P/E of 15x, which sits well below several key comparison points in the biotech space.

    The P/E multiple compares the current share price with the company’s earnings per share. For a biopharmaceutical business like HBM Holdings, it reflects how the market values the current earnings stream from its antibody platform and pipeline projects.

    HBM Holdings is described as good value on P/E when lined up against both the Asian biotech industry average of 31.4x and a peer average of 46.2x. That is a wide gap. However, the estimated fair P/E for the stock is 10.3x, which implies the current 15x multiple sits above the level that regression based modelling suggests the market could move towards over time.

    Explore the SWS fair ratio for HBM Holdings

    Result: Price-to-Earnings of 15x (ABOUT RIGHT)

    However, HBM Holdings still faces risks, including pressure on revenue and net income growth, and the possibility that intrinsic value estimates will continue to lag the current share price.

    Find out about the key risks to this HBM Holdings narrative.

    Another view on HBM Holdings using cash flows

    The P/E comparison paints HBM Holdings as cheaper than many biotech peers, yet the SWS DCF model points in a different direction. At HK$12.40, the stock trades above an estimated cash flow value of HK$9.22, which implies a premium to the model’s view of fair value. That raises a practical question for investors: Which signal deserves more weight, the earnings multiple or the cash flow math?

    Look into how the SWS DCF model arrives at its fair value.

    2142 Discounted Cash Flow as at Jul 2026
    2142 Discounted Cash Flow as at Jul 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 246 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    With mixed signals around HBM Holdings, it makes sense to move fast and review the full picture for yourself instead of relying on headlines alone. To weigh the upside potential against the concerns in a balanced way, start by checking the 2 key rewards and 2 important warning signs

    Looking for more investment ideas beyond HBM Holdings?

    If HBM Holdings has sharpened your focus on opportunities, do not stop here. Use the tools available now so you do not miss other compelling setups.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.